ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
FRA:ZEG - Deutsche Boerse Ag - GB0009895292 - Common Stock - Currency: EUR
Overall ZEG gets a fundamental rating of 5 out of 10. We evaluated ZEG against 50 industry peers in the Pharmaceuticals industry. While ZEG has a great profitability rating, there are some minor concerns on its financial health. ZEG has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ZEG was profitable.
ZEG had a positive operating cash flow in the past year.
In the past 5 years ZEG has always been profitable.
In the past 5 years ZEG always reported a positive cash flow from operatings.
1.2 Ratios
ZEG has a Return On Assets of 6.76%. This is in the better half of the industry: ZEG outperforms 68.00% of its industry peers.
ZEG's Return On Equity of 17.25% is fine compared to the rest of the industry. ZEG outperforms 70.00% of its industry peers.
ZEG has a Return On Invested Capital of 13.99%. This is in the better half of the industry: ZEG outperforms 76.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ZEG is below the industry average of 14.89%.
The last Return On Invested Capital (13.99%) for ZEG is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.76% | ||
| ROE | 17.25% | ||
| ROIC | 13.99% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.53%
1.3 Margins
With a decent Profit Margin value of 13.01%, ZEG is doing good in the industry, outperforming 68.00% of the companies in the same industry.
ZEG's Profit Margin has improved in the last couple of years.
The Operating Margin of ZEG (23.64%) is better than 72.00% of its industry peers.
In the last couple of years the Operating Margin of ZEG has grown nicely.
ZEG has a Gross Margin of 82.13%. This is amongst the best in the industry. ZEG outperforms 82.00% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.64% | ||
| PM (TTM) | 13.01% | ||
| GM | 82.13% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ZEG is creating some value.
The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ZEG has more shares outstanding
ZEG has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.04 indicates that ZEG is not in any danger for bankruptcy at the moment.
ZEG has a better Altman-Z score (5.04) than 82.00% of its industry peers.
The Debt to FCF ratio of ZEG is 4.16, which is a neutral value as it means it would take ZEG, 4.16 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.16, ZEG is in the better half of the industry, outperforming 64.00% of the companies in the same industry.
ZEG has a Debt/Equity ratio of 0.69. This is a neutral value indicating ZEG is somewhat dependend on debt financing.
ZEG has a Debt to Equity ratio of 0.69. This is comparable to the rest of the industry: ZEG outperforms 52.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 4.16 | ||
| Altman-Z | 5.04 |
ROIC/WACC1.57
WACC8.93%
2.3 Liquidity
ZEG has a Current Ratio of 0.93. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ZEG (0.93) is worse than 80.00% of its industry peers.
A Quick Ratio of 0.74 indicates that ZEG may have some problems paying its short term obligations.
The Quick ratio of ZEG (0.74) is worse than 78.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.24%, which is quite good.
Measured over the past years, ZEG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.59% on average per year.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 18.03% in the last year.
The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)13.24%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%44.14%
Revenue 1Y (TTM)18.03%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%23.84%
3.2 Future
ZEG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.41% yearly.
ZEG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.41% yearly.
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.41%
Revenue Next Year8.09%
Revenue Next 2Y7.05%
Revenue Next 3Y6.58%
Revenue Next 5Y6.41%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.86, ZEG is valued correctly.
Based on the Price/Earnings ratio, ZEG is valued a bit cheaper than 62.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.79. ZEG is valued slightly cheaper when compared to this.
ZEG is valuated correctly with a Price/Forward Earnings ratio of 14.99.
ZEG's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of ZEG to the average of the S&P500 Index (21.38), we can say ZEG is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.86 | ||
| Fwd PE | 14.99 |
4.2 Price Multiples
ZEG's Enterprise Value to EBITDA is on the same level as the industry average.
ZEG's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59 | ||
| EV/EBITDA | 23.29 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.35
PEG (5Y)0.91
EPS Next 2Y12.94%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.35%, ZEG has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 3.11, ZEG pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.47, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.35% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
65.80% of the earnings are spent on dividend by ZEG. This is not a sustainable payout ratio.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP65.8%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
FRA:ZEG (4/25/2025, 7:00:00 PM)
121.9
-0.4 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.67%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap377.93B
Analysts82.86
Price Target163.45 (34.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.35% |
Yearly Dividend2.63
Dividend Growth(5Y)1.4%
DP65.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0%
Min EPS beat(2)-0.63%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)0.75%
Min EPS beat(4)-1.9%
Max EPS beat(4)4.9%
EPS beat(8)5
Avg EPS beat(8)2.17%
EPS beat(12)9
Avg EPS beat(12)3.59%
EPS beat(16)11
Avg EPS beat(16)2.29%
Revenue beat(2)2
Avg Revenue beat(2)1.82%
Min Revenue beat(2)0.95%
Max Revenue beat(2)2.7%
Revenue beat(4)3
Avg Revenue beat(4)1.85%
Min Revenue beat(4)-0.52%
Max Revenue beat(4)4.27%
Revenue beat(8)4
Avg Revenue beat(8)0.17%
Revenue beat(12)5
Avg Revenue beat(12)-0.07%
Revenue beat(16)9
Avg Revenue beat(16)1.08%
PT rev (1m)-4.67%
PT rev (3m)0.26%
EPS NQ rev (1m)-1.06%
EPS NQ rev (3m)-6.87%
EPS NY rev (1m)-0.16%
EPS NY rev (3m)-3.74%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)-0.92%
Revenue NY rev (1m)0.57%
Revenue NY rev (3m)1.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.86 | ||
| Fwd PE | 14.99 | ||
| P/S | 7.94 | ||
| P/FCF | 59 | ||
| P/OCF | 36.19 | ||
| P/B | 10.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.29 |
EPS(TTM)7.23
EY5.93%
EPS(NY)8.13
Fwd EY6.67%
FCF(TTM)2.07
FCFY1.69%
OCF(TTM)3.37
OCFY2.76%
SpS15.36
BVpS11.58
TBVpS-4.95
PEG (NY)1.35
PEG (5Y)0.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.76% | ||
| ROE | 17.25% | ||
| ROCE | 16.78% | ||
| ROIC | 13.99% | ||
| ROICexc | 15.1% | ||
| ROICexgc | 84.63% | ||
| OM | 23.64% | ||
| PM (TTM) | 13.01% | ||
| GM | 82.13% | ||
| FCFM | 13.45% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.53%
ROICexc(3y)12.66%
ROICexc(5y)10.56%
ROICexgc(3y)112.76%
ROICexgc(5y)85.62%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexcg growth 3Y43.28%
ROICexcg growth 5Y4.46%
ROICexc growth 3Y41%
ROICexc growth 5Y11.95%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 4.16 | ||
| Debt/EBITDA | 1.44 | ||
| Cap/Depr | 68.57% | ||
| Cap/Sales | 8.48% | ||
| Interest Coverage | 9.73 | ||
| Cash Conversion | 60.92% | ||
| Profit Quality | 103.41% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 5.04 |
F-Score7
WACC8.93%
ROIC/WACC1.57
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)13.24%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%44.14%
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.41%
Revenue 1Y (TTM)18.03%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%23.84%
Revenue Next Year8.09%
Revenue Next 2Y7.05%
Revenue Next 3Y6.58%
Revenue Next 5Y6.41%
EBIT growth 1Y43.36%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year30.69%
EBIT Next 3Y16.62%
EBIT Next 5Y13.31%
FCF growth 1Y10.78%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y14.65%
OCF growth 3Y25.76%
OCF growth 5Y31.92%